» Articles » PMID: 11897007

Anti-Gal Alpha 1-3Gal IgM and IgG Antibody Levels in Sera of Humans and Old World Non-human Primates

Overview
Specialty General Surgery
Date 2002 Mar 19
PMID 11897007
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Organs transplanted from pig to primate are rejected within minutes or hours by an antibody-dependent, complement-mediated mechanism [hyperacute rejection (HAR)]. Even after depletion of anti-Gal alpha 1-3Gal (Gal) antibody (Ab), for example by extracorporeal immunoadsorption, return of natural Ab is believed to be a major factor in the initiation of acute humoral xenograft rejection. Various non-human primates are used as recipients of pig organs in experimental discordant xenotransplantation (XTx) models. However, anti-Gal IgM and IgG levels in non-human primates may differ from those in humans. Serum levels of anti-Gal IgM and IgG were measured by enzyme-linked immunosorbent assay (ELISA) in humans (n=14), chimpanzees (n=8), baboons (n=214), cynomolgus monkeys (n=29), rhesus monkeys (n=23) and Japanese monkeys (n=6). The mean level of anti-Gal IgM was significantly higher in chimpanzees than in other groups, while in rhesus monkeys it was significantly lower than in other groups, except baboons and Japanese monkeys. The mean human anti-Gal IgG level was higher than in other groups and this difference reached statistical significance except with regard to chimpanzees. The mean anti-Gal IgG level in baboons was significantly lower than that in humans, chimpanzees and cynomolgus monkeys. The measured differences in anti-Gal IgM and IgG levels may affect the kinetics of Ab removal and rate of return in different species, and thus may have relevance for translating work in non-human primate models to the clinical setting.

Citing Articles

Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies.

Galili U Front Mol Biosci. 2023; 10:1209974.

PMID: 37449060 PMC: 10338101. DOI: 10.3389/fmolb.2023.1209974.


Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.

Galili U Med Res Arch. 2021; 9(7).

PMID: 34853815 PMC: 8631339. DOI: 10.18103/mra.v9i7.2481.


Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies.

Galili U Front Mol Biosci. 2021; 8:746883.

PMID: 34805272 PMC: 8601398. DOI: 10.3389/fmolb.2021.746883.


Capillary (Gel) Electrophoresis-Based Methods for Immunoglobulin (G) Glycosylation Analysis.

Cajic S, Hennig R, Burock R, Rapp E Exp Suppl. 2021; 112:137-172.

PMID: 34687009 DOI: 10.1007/978-3-030-76912-3_4.


Near Complete Repair After Myocardial Infarction in Adult Mice by Altering the Inflammatory Response With Intramyocardial Injection of α-Gal Nanoparticles.

Galili U, Zhu Z, Chen J, Goldufsky J, Schaer G Front Cardiovasc Med. 2021; 8:719160.

PMID: 34513957 PMC: 8425953. DOI: 10.3389/fcvm.2021.719160.